• 1
    Ries LAG, Krapcho M, Stinchcomb DG, et al, eds. SEER Cancer Statistics Review, 1975-2005. Bethesda, Md: National Cancer Institute; Year. Available at: Accessed on March 1, 2009.
  • 2
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
  • 3
    National Comprehensive Cancer Network. Guidelines. Available at: gls/f_guidelines.asp. Accessed on March 1, 2009.
  • 4
    Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999; 17: 2365-2370.
  • 5
    Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992; 166: 788-793.
  • 6
    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996; 14: 1718-1729.
  • 7
    Smith IE, Dowsett M, Yap YS, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006; 24: 2444-2447.
  • 8
    Anders C, Marcom PK, Peterson B, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 2008; 26: 286-295.
  • 9
    Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006; 21: 2583-2592.
  • 10
    Lutchman Singh K, Muttukrishna S, Stein RC, et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007; 96: 1808-1816.
  • 11
    Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod. 2003; 18: 2368-2374.
  • 12
    Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab. 2003; 88: 5307-5314.
  • 13
    Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update. 2005; 11: 69-89.
  • 14
    Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006; 24: 5769-5779.
  • 15
    Freeman EW, Sammel MD, Gracia CR, et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril. 2005; 83: 383-392.
  • 16
    Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF III. Association of anti-Mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril. 2007; 87: 101-106.
  • 17
    Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986; (1): 105-109.
  • 18
    Poikonen P, Saarto T, Elomaa I, Joensuu H, Blomqvist C. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur J Cancer. 2000; 36: 43-48.
  • 19
    Rose DP, Davis TE. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 1980; 40: 4043-4047.
  • 20
    Samaan NA, deAsis DN Jr, Buzdar AU, Blumenschein GR. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer. 1978; 41: 2084-2087.
  • 21
    Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod. 2005; 20: 923-927.
  • 22
    Ellmen J, Hakulinen P, Partanen A, Hayes DF. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat. 2003; 82: 103-111.
  • 23
    Jordan VC, Fritz NF, Tormey DC. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987; 47: 624-630.
  • 24
    Gracia CR, Sammel MD, Freeman EW, et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause. 2005; 12: 128-135.
  • 25
    Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric. 2001; 4: 267-272.
  • 26
    Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006; 12: 685-718.
  • 27
    Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-Mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008; 93: 3478-3483.
  • 28
    van Disseldorp J, Faddy MJ, Themmen AP, et al. Relationship of serum antimullerian hormone concentration to age at menopause. J Clin Endocrinol Metab. 2008; 93: 2129-2134.
  • 29
    Burger HG, Hee JP, Mamers P, Bangah M, Zissimos M, McCloud PI. Serum inhibin during lactation: relation to the gonadotrophins and gonadal steroids. Clin Endocrinol (Oxf). 1994; 41: 771-777.
  • 30
    Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum Reprod Update. 2007; 13: 559-565.
  • 31
    van Rooij IA, Tonkelaar I, Broekmans FJ, et al. Anti-Mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause. 2004; 11( 6 pt 1): 601-606.
  • 32
    de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002; 77: 357-362.
  • 33
    Speroff MAFL. Clinical Gynecologic Endocrinology & Infertility. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006.
  • 34
    Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008; 113: 2385-2397.